Genome-edited Cells
Bone
The CMTM6 Knockout Raji Cell Line is a CRISPR/Cas9-edited B lymphocyte model with disruption of the CMTM6 gene, a key stabilizer of PD-L1 and PD-L2. In the Raji Burkitt lymphoma background, loss of CMTM6 accelerates lysosomal degradation of PD-L1, impairing immune checkpoint function. This line enables direct study of PD-L1 regulation and recycling endosome dynamics. Applications include flow cytometric PD-L1 measurement, co-immunoprecipitation of PD-L1?CCMTM6 complexes, and T-cell co-culture assays. It is suitable for drug screens targeting PD-L1 stability and for investigating SHP-2 and JAK/STAT signaling downstream of PD-1.
MTCH1 Knockout SK-HEP-1 Polyclonal Cells
Cat. No. ARG15700
L1CAM Knockout huh-7 Polyclonal Cells
Cat. No. ARG28510
IGF2R Knockout NCI-H1299 Polyclonal Cells
Cat. No. ARG30809
HK1 Knockout HCT116 Polyclonal Cells
Cat. No. ARG34781
CAPNS2 Knockout Hela Polyclonal Cells
Cat. No. ARG42239
NAMPT Knockout Raji Polyclonal Cells
Cat. No. ARG1783
The CMTM6 Knockout Raji Cell Line is a CRISPR/Cas9-edited knockout model in which the CMTM6 gene has been disrupted, eliminating its function in PD-L1 stabilization. Derived from the Raji human B lymphocyte line, this cell line provides a defined loss-of-function system for dissecting CMTM6-dependent regulation of PD-L1 surface expression and endosomal recycling. By removing the protective interaction, researchers can study enhanced PD-L1 degradation and altered immune checkpoint output.
The Raji parental line originates from a human Burkitt lymphoma and represents a lymphoblastoid B-cell lineage. Raji cells are characterized by rapid proliferation and express key immunomodulatory molecules, making them a standard model for B-cell lymphoma and immune evasion research. This genetic background is clinically relevant for investigating PD-L1 checkpoint mechanisms in hematologic malignancies.
CMTM6 (CKLF-like MARVEL transmembrane domain containing 6) is a ubiquitously expressed protein that directly binds PD-L1 and PD-L2 at the plasma membrane and in recycling endosomes. By shielding PD-L1 from ubiquitination and subsequent lysosomal sorting, CMTM6 prolongs its half-life and increases steady-state surface levels. Elevated PD-L1 engages PD-1 on T cells, recruiting SHP-2 phosphatase and dampening ZAP70-mediated T-cell receptor signaling, thus suppressing anti-tumor immunity. The pathway integrates input from the IFN-gamma receptor and JAK/STAT activation, while CMTM6 itself lacks known upstream regulators, making its disruption a direct means to reduce PD-L1 load.
In the Raji lymphoma context, CMTM6 knockout significantly reduces PD-L1 surface expression, impairing immune evasion capacity. This model enables rigorous examination of the molecular interplay between endosomal recycling, lysosomal degradation, and checkpoint protein turnover. It serves as a platform for mapping PD-L1 degradation pathways and testing interventions that bypass CMTM6 to destabilize PD-L1, with direct relevance for B-cell lymphoma therapies.
Typical applications include flow cytometry and immunofluorescence to quantify surface PD-L1, co-immunoprecipitation to assess PD-L1?CCMTM6 interaction, and T-cell co-culture assays to measure functional immune suppression. The cell line is also suitable for drug screens targeting PD-L1 stability and for mechanistic studies on lysosomal inhibition and JAK/STAT signaling. For additional information or technical support, please contact Ascent Research.
